drugset / Trial / NCT00762463

Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

NCT00762463

Phase 3 Completed 240 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).

Timeline

Start
2009-07
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Subject Celecoxib Other / unclassified 400 mg
Comparator Diclofenac SR Unknown 75 mg